Interactions between gadodiamide and Tyropanoate (tyropanoate)
tyropanoate and gadodiamide (Moderate Drug-Drug)
MANAGEMENT: Administration of any intravascular contrast agent should be deferred for 48 hours in patients with hepatic or biliary disorders who have recently received an oral cholecystographic contrast agent.





